Belatacept

• Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAemia after kidney… Pending
  2024-517219-56-00 Phase IV 1 country Paediatrisches Forschungsnetzwerk gGmbH; PROFIL Institut fuer Stoffwechselforsch…
• SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety stu… Pending
  2025-525091-29-00 Phase II 1 country Medical University Of Vienna
• Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kid… Recruiting
  2024-516527-13-00 Phase III/IV 1 country Centre Hospitalier Universitaire Rouen
• Interest of belatacept as a non-nephrotoxic immunosuppressive treatment in cardiac transplant patients at risk of chronic renal failure. Recruiting
  2024-516541-40-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the… Recruiting
  2022-501677-39-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
• Comparison of the effects of Belatacept and Anticalcineurins on endothelial function in kidney transplant patients - BELAFENDO Recruiting
  2024-515577-10-00 Phase IV 1 country Centre Hospitalier Universitaire Rouen
• BELASBRIDGE : Belatacept as a replacement for CNIs 3 to 12 months post-transplantation in patients with early graft dysfunction Ended
  2022-500299-71-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes

Showing 1–7 of 7 trials